Mark Connolly

Summary

Publications

  1. ncbi request reprint The economics of mesalazine in active ulcerative colitis and maintenance in the Netherlands
    M P Connolly
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, The Netherlands
    Neth J Med 70:272-7. 2012
  2. doi request reprint The impact of rotavirus vaccination on discounted net tax revenue in egypt: a government perspective analysis
    Mark P Connolly
    Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Pharmacoeconomics 30:681-95. 2012
  3. pmc Atosiban versus betamimetics in the treatment of preterm labour in Germany: an economic evaluation
    Jaro Wex
    PharmArchitecture Limited, Quatro House, Surrey, UK
    BMC Pregnancy Childbirth 9:23. 2009
  4. doi request reprint Cross-border reproductive care: market forces in action or market failure? An economic perspective
    Mark Connolly
    Global Market Access Solutions, St Prex, Switzerland
    Reprod Biomed Online 23:817-9. 2011
  5. doi request reprint Kiovig for primary immunodeficiency: reduced infusion and decreased costs per infusion
    Mark Connolly
    Global Market Access Solutions, Switzerland
    Int Immunopharmacol 11:1358-61. 2011
  6. doi request reprint Economics of assisted reproduction: access to fertility treatments and valuing live births in economic terms
    Mark P Connolly
    Department of Pharmacy, Unit of Pharmacoepidemiology and Pharmacoeconomics, University of Groningen, Groningen, The Netherlands
    Hum Fertil (Camb) 13:13-8. 2010
  7. doi request reprint Quality of life improvements attributed to combination therapy with oral and topical mesalazine in mild-to-moderately active ulcerative colitis
    M P Connolly
    Global Market Access Solutionsr, St Prex, Switzerland
    Digestion 80:241-6. 2009
  8. doi request reprint The impact of introducing patient co-payments in Germany on the use of IVF and ICSI: a price-elasticity of demand assessment
    M P Connolly
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Hum Reprod 24:2796-800. 2009
  9. ncbi request reprint A cost per live birth comparison of HMG and rFSH randomized trials
    Mark Connolly
    Market Access, Ferring International Centre, St Prex, Switzerland
    Reprod Biomed Online 17:756-63. 2008
  10. doi request reprint Assessing long-run economic benefits attributed to an IVF-conceived singleton based on projected lifetime net tax contributions in the UK
    M Connolly
    Health Economics, Global Market Access Solutions, St Prex 1162, Switzerland
    Hum Reprod 24:626-32. 2009

Collaborators

Detail Information

Publications12

  1. ncbi request reprint The economics of mesalazine in active ulcerative colitis and maintenance in the Netherlands
    M P Connolly
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, The Netherlands
    Neth J Med 70:272-7. 2012
    ....
  2. doi request reprint The impact of rotavirus vaccination on discounted net tax revenue in egypt: a government perspective analysis
    Mark P Connolly
    Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Pharmacoeconomics 30:681-95. 2012
    ..The assumption was that increased childhood survival in vaccinated cohorts leads to increased numbers of children consuming government resource, and an increased number of future tax payers...
  3. pmc Atosiban versus betamimetics in the treatment of preterm labour in Germany: an economic evaluation
    Jaro Wex
    PharmArchitecture Limited, Quatro House, Surrey, UK
    BMC Pregnancy Childbirth 9:23. 2009
    ..We aimed to compare economic implications of tocolysis using atosiban and betamimetics, considering treatment efficacy and safety, as well as cost consequences of treatment of associated adverse events...
  4. doi request reprint Cross-border reproductive care: market forces in action or market failure? An economic perspective
    Mark Connolly
    Global Market Access Solutions, St Prex, Switzerland
    Reprod Biomed Online 23:817-9. 2011
    ..To counter funding challenges, there is a need to communicate the medical benefits of assisted reproduction and the economic benefits that these children will offer in an era of austerity and ageing populations...
  5. doi request reprint Kiovig for primary immunodeficiency: reduced infusion and decreased costs per infusion
    Mark Connolly
    Global Market Access Solutions, Switzerland
    Int Immunopharmacol 11:1358-61. 2011
    ..Reduced costs per infusion were attributed to lower costs associated with treating adverse events and the opportunity cost of nursing time and time off work for working adults...
  6. doi request reprint Economics of assisted reproduction: access to fertility treatments and valuing live births in economic terms
    Mark P Connolly
    Department of Pharmacy, Unit of Pharmacoepidemiology and Pharmacoeconomics, University of Groningen, Groningen, The Netherlands
    Hum Fertil (Camb) 13:13-8. 2010
    ....
  7. doi request reprint Quality of life improvements attributed to combination therapy with oral and topical mesalazine in mild-to-moderately active ulcerative colitis
    M P Connolly
    Global Market Access Solutionsr, St Prex, Switzerland
    Digestion 80:241-6. 2009
    ....
  8. doi request reprint The impact of introducing patient co-payments in Germany on the use of IVF and ICSI: a price-elasticity of demand assessment
    M P Connolly
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Hum Reprod 24:2796-800. 2009
    ..In 2004 German health authorities introduced a 50% co-payment for patients, in an effort to save cost. We explored the impact of this pricing policy on the utilization of reproductive treatments in Germany...
  9. ncbi request reprint A cost per live birth comparison of HMG and rFSH randomized trials
    Mark Connolly
    Market Access, Ferring International Centre, St Prex, Switzerland
    Reprod Biomed Online 17:756-63. 2008
    ..Within a fixed healthcare budget, the cost-savings achieved using HP-HMG would allow for the delivery of additional IVF cycles...
  10. doi request reprint Assessing long-run economic benefits attributed to an IVF-conceived singleton based on projected lifetime net tax contributions in the UK
    M Connolly
    Health Economics, Global Market Access Solutions, St Prex 1162, Switzerland
    Hum Reprod 24:626-32. 2009
    ..Despite increasing demand, health authorities often view infertility as a low health priority and consequently limit access to treatments by rationing and limiting funds...
  11. ncbi request reprint An economic evaluation of vasoactive agents used to treat acute bleeding oesophageal varices in Belgium
    Mark Connolly
    Ferring International Center, St Prex, Switzerland
    Acta Gastroenterol Belg 71:230-6. 2008
    ..In light of the need to control costs, an economic evaluation of vasoactive agents used to treat cirrhotic patients with BOV within the emergency setting in Belgium has been assessed...
  12. ncbi request reprint An economic evaluation of vasoactive agents used in the United Kingdom for acute bleeding oesophageal varices in patients with liver cirrhosis
    Jaroslaw Wechowski
    Cardiff Research Consortium, University Hospital of Wales, Cardiff, UK
    Curr Med Res Opin 23:1481-91. 2007
    ..To conduct an economic evaluation of terlipressin, octreotide and placebo in the treatment of bleeding oesophageal varices (BOV) where endotherapy could be used concomitantly...